Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Julien Edeline
Systematic review and pooled analysis of locoregional therapies in patients with intrahepatic cholangiocarcinoma
Background Locoregional treatments (LRT) including radioembolisation (SIRT), transarterial chemo-embolisation (TACE), hepatic arterial infusion (HAI) of chemotherapy, ex...
Julien Edeline ;
Timothy Jacobs ;
Richard A. Hubner ;
Dan Palmer ;
Philip Johnson ;
Boris Guiu ;
Juan W. Valle ;
Angela Lamarca , MD, PhD, MSc;
06/28/2021
Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240
BackgroundPembro received accelerated approval for second-line therapy in pts with advanced HCC, based on the phase 2, KEYNOTE-224 trial. KEYNOTE-240 was a randomized, phase 3 study of P...
Marcelo Garrido ;
Stephen Lam Chan , MD;
Jennifer J. Knox ;
Bruno Daniele ;
Scot Ebbinghaus ;
Erluo Chen ;
Abby B. Siegel ;
Julien Edeline ;
Baek-Yeol Ryoo ;
Ann-Lii Cheng , MD, PhD;
Philippe Merle ;
Masatoshi Kudo , MD, PhD;
Mohamed Bouattour ;
Richard S. Finn ;
Ho-Yeong Lim ;
Andrew Zhu ;
Valeriy Vladimirovich Breder , MD, PhD;
Yee Chao ;
Sadahisa Ogasawara ;
Thomas Yau ;
07/01/2019
Featured CME Course
Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes
Upcoming Events
February 2 – February 5
February 7 – February 9
February 27 – March 1
March 17 – March 19
March 22 – March 23
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
May 1 – May 3
See Full Calendar